U.K. company develops weapon against hospital 'superbug'

Difficile strikes when antibiotics kill all the 'good bugs' that dwell in your gut--like the ones that aid in digestion--and leave only C. difficile, which then causes severe diarrhea and could lead to colon infections.
Clostridium difficile: Yes, it is just as nasty as it sounds. C. difficile is a "superbug" that is the scourge of hospitals. It strikes when antibiotics kill all the "good bugs" that dwell in your gut--like the ones that aid in digestion--and leave only C. difficile, which then causes severe diarrhea and could lead to colon infections.
Researchers at Summit, a U.K.-based drug discovery company, thinks it's found an answer to C. difficile with a new antibiotic it is developing with help from a Wellcome Trust Seeding Drug Discovery award. According to an article by the Wellcome Trust, Summit's new antibiotic "clears C. difficile and provides total protection from recurrence in an animal model of infection." The compound also leaves the natural populations of bacteria in the gut unharmed, Wellcome says.
William Weiss, director of pre-clinical services at the University of North Texas Health Science Center in Fort Worth, who collaborated on the preclinical studies, is ho
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News PSCI launches progressive position on the use of Horseshoe Crabs
A quarterly series of articles about responsible supply chain management from the PSCI. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research. -
News Thermo Fisher Scientific opens new steriles drug manufacturing site in Singapore
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region. -
News Medicines for All receive $18.7 million grant for expansion of global access to lifesaving medication
Funded by the Bill & Melinda Gates Foundation, the Virginia Commonwealth University-based research-related institute will use the grant to expand on its current capabilities of bringing lifesaving medications around the world, as well as working on 14 ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance